Magnetoferritin nanoparticles for targeting and visualizing tumour tissues.

[1]  C. H. Buckley,et al.  p53 expression in carcinoma of the cervix. , 1996, Journal of clinical pathology.

[2]  D. He,et al.  [Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues]. , 2008, Ai zheng = Aizheng = Chinese journal of cancer.

[3]  R. Haba,et al.  Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. , 2005, The Journal of urology.

[4]  S. Ménard,et al.  A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. , 1996, Cancer research.

[5]  M. Young,et al.  Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. , 2006, Journal of the American Chemical Society.

[6]  O. Lin,et al.  Cervical squamous dysplasias and carcinomas with immunodetectable p53 frequently contain HPV. , 1995, Gynecologic oncology.

[7]  R. Kudo,et al.  ras oncogene expression and prognosis of invasive squamous cell carcinomas of the uterine cervix , 1989, Cancer.

[8]  Jae Hyuk Lee,et al.  Expression of p16, p53, and Ki-67 in colorectal adenocarcinoma: a study of 356 surgically resected cases. , 2010, Hepato-gastroenterology.

[9]  W. Frankel,et al.  Immunohistochemical Analysis of Hepatocellular and Adenocarcinoma in the Liver: MOC31 Compares Favorably with Other Putative Markers , 2000, Modern Pathology.

[10]  Efstathios Karathanasis,et al.  Multifunctional nanocarriers for mammographic quantification of tumor dosing and prognosis of breast cancer therapy. , 2008, Biomaterials.

[11]  V. H. Lee,et al.  Prodrugs for improved ocular drug delivery , 1989 .

[12]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[13]  H. Fox,et al.  Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. , 1992, Journal of clinical pathology.

[14]  Hengyi Xu,et al.  Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. , 2011, Biomaterials.

[15]  Thomas Kelly,et al.  In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. , 2009, Nature nanotechnology.

[16]  S. Mann,et al.  Magnetoferritin: in vitro synthesis of a novel magnetic protein. , 1992, Science.

[17]  Kwangmeyung Kim,et al.  Hybrid ferritin nanoparticles as activatable probes for tumor imaging. , 2011, Angewandte Chemie.

[18]  C. Ballestín,et al.  Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[19]  D. Burstein,et al.  p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. , 2003, American journal of clinical pathology.

[20]  D. Larsimont,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. , 2000, American journal of clinical pathology.

[21]  Chad A Mirkin,et al.  Multiplexed detection of protein cancer markers with biobarcoded nanoparticle probes. , 2006, Journal of the American Chemical Society.

[22]  W. Seaman,et al.  Binding and uptake of H-ferritin are mediated by human transferrin receptor-1 , 2010, Proceedings of the National Academy of Sciences.

[23]  M. Srougi,et al.  Cdx2, cytokeratin 20, thyroid transcription factor 1, and prostate-specific antigen expression in unusual subtypes of prostate cancer. , 2008, Annals of diagnostic pathology.

[24]  R. B. Grubbs.  Roles of Polymer Ligands in Nanoparticle Stabilization , 2007 .

[25]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[26]  Fan Zhang,et al.  Chimeric ferritin nanocages for multiple function loading and multimodal imaging. , 2011, Nano letters.

[27]  P. Chu,et al.  Hepatocyte Antigen as a Marker of Hepatocellular Carcinoma: An Immunohistochemical Comparison to Carcinoembryonic Antigen, CD10, and Alpha-Fetoprotein , 2002, The American journal of surgical pathology.

[28]  Elizabeth C. Theil.  Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. , 1987, Annual review of biochemistry.

[29]  A. Khabir,et al.  Correlation Between Immunohistochemical Biomarkers Expression and Prognosis of Ovarian Carcinomas in Tunisian Patients , 2010, World journal of oncology.

[30]  Christian Bergemann,et al.  Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles. , 2009, Cancer research.

[31]  V. Abeler,et al.  Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c‐erbB‐2 in early cervical squamous cell carcinoma: An immunohistochemical study , 1996, Cancer.

[32]  E. Diamandis,et al.  Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. , 1997, American journal of clinical pathology.

[33]  A. Gown,et al.  P504S Immunohistochemical Detection in 405 Prostatic Specimens Including 376 18-Gauge Needle Biopsies , 2002, The American journal of surgical pathology.

[34]  A. S. Moses,et al.  Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.

[35]  M. Büchler,et al.  Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. , 2004, European journal of cancer.

[36]  W. Jonat,et al.  p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity , 2005, Journal of Cancer Research and Clinical Oncology.

[37]  C. Kainz,et al.  Mutant p53 in patients with invasive cervical cancer stages IB to IIB. , 1995, Gynecologic oncology.

[38]  Hong Dai,et al.  Imaging , Diagnosis , Prognosis Prognostic Value of Akt1 in Human Prostate Cancer : A Computerized Quantitative Assessment with Quantum Dot Technology , 2009 .

[39]  D. Spandidos,et al.  Immunohistochemical study of ras oncogene expression in endometrial and cervical human lesions. , 1988, European journal of gynaecological oncology.

[40]  R. Walker,et al.  Transferrin receptor expression in non‐malignant and malignant human breast tissue , 1986, The Journal of pathology.

[41]  Zhong Jiang,et al.  Using an AMACR (P504S)/34betaE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. , 2005, American journal of clinical pathology.

[42]  R. Weissleder,et al.  Cell-specific targeting of nanoparticles by multivalent attachment of small molecules , 2005, Nature Biotechnology.

[43]  Ximing J. Yang,et al.  P504S/&agr;-Methylacyl-CoA Racemase: A Useful Marker for Diagnosis of Small Foci of Prostatic Carcinoma on Needle Biopsy , 2002, The American journal of surgical pathology.

[44]  Yanlei Ma,et al.  Immunohistochemical analysis revealed CD34 and Ki67 protein expression as significant prognostic factors in colorectal cancer , 2010, Medical oncology.

[45]  B. Slotman,et al.  Endocrine role in ovarian cancer , 1996 .

[46]  Ick Chan Kwon,et al.  A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[47]  T. Molina,et al.  Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin , 2005, Modern Pathology.

[48]  M. Young,et al.  Protein Cage Constrained Synthesis of Ferrimagnetic Iron Oxide Nanoparticles , 2002 .

[49]  A. Thor,et al.  p53 gene mutations and protein accumulation in human ovarian cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Varma,et al.  Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: Implications for diagnostic prostatic pathology. , 2002, American journal of clinical pathology.

[51]  Weipeng Cao,et al.  Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. , 2012, Biomaterials.

[52]  Yu Zhang,et al.  Intrinsic peroxidase-like activity of ferromagnetic nanoparticles. , 2007, Nature nanotechnology.

[53]  K. Oka,et al.  c‐erbB‐2 oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix , 1994, Cancer.

[54]  A. Malliri,et al.  Ras and p53 expression in non-small-cell lung-cancer patients - p53 over-expression correlates with a poor prognosis. , 1992, International journal of oncology.

[55]  Samir Mitragotri,et al.  Designer Biomaterials for Nanomedicine , 2009 .

[56]  T. Daniels,et al.  The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. , 2006, Clinical immunology.

[57]  M. O’Donnell,et al.  Multifunctional nanoparticles as coupled contrast agents. , 2010, Nature communications.

[58]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[59]  S. Arabia,et al.  The Diagnostic Value of Immunohistochemistry in the Diagnosis of Primary and Secondary Hepatic Carcinomas , 2009 .

[60]  C. Chai,et al.  Role Of TTF‐1, CK20, And CK7 Immunohistochemistry for Diagnosis of Primary and Secondary Lung Adenocarcinoma , 2006, The Kaohsiung journal of medical sciences.

[61]  Weihong Tan,et al.  Surface modification of silica nanoparticles to reduce aggregation and nonspecific binding. , 2006, Langmuir : the ACS journal of surfaces and colloids.

[62]  S. Gambhir,et al.  Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics , 2005, Science.

[63]  M. Sajin,et al.  Ki-67, p53 and bcl-2 analysis in colonic versus rectal adenocarcinoma. , 2008, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[64]  I. Busmanis.  Biomarkers in carcinoma of the cervix: emphasis on tissue-related factors and their potential prognostic factors. , 1998, Annals of the Academy of Medicine, Singapore.

[65]  M. Tzardi,et al.  Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas , 1999, Medical oncology.

[66]  Xiaohu Gao,et al.  Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. , 2010, Chemical Society reviews.

[67]  D. Landsittel,et al.  Early identification of individuals with prostate cancer in negative biopsies. , 2004, The Journal of urology.

[68]  Xinying Wu,et al.  Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. , 2010, Biomaterials.

[69]  O. Bae,et al.  CEA Expressions in Colorectal Tumor , 2004 .

[70]  A. Parwani,et al.  Immunohistochemical Staining of Precursor Forms of Prostate-specific Antigen (proPSA) in Metastatic Prostate Cancer , 2006, The American journal of surgical pathology.

[71]  F. Torti,et al.  Recombinant ferritin: modulation of subunit stoichiometry in bacterial expression systems. , 1997, Protein engineering.

[72]  A. Kassner,et al.  Molecular Imaging of Angiogenesis in Nascent Vx-2 Rabbit Tumors Using a Novel ανβ3-targeted Nanoparticle and 1.5 Tesla Magnetic Resonance Imaging , 2003 .

[73]  F. Rath,et al.  Tumor hypoxia, p53, and prognosis in cervical cancers. , 2001, International journal of radiation oncology, biology, physics.

[74]  J. V. Bannister,et al.  Structure and composition of ferritin cores isolated from human spleen, limpet (Patella vulgata) hemolymph and bacterial (Pseudomonas aeruginosa) cells. , 1986, Journal of molecular biology.

[75]  H. Isbell.  Haworth Memorial Lecture. The Haworth–Hudson controversy and the development of Haworth's concepts of ring conformation and of neighbouring group effects , 1974 .

[76]  M. Greaves,et al.  Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Serena Mazzucchelli,et al.  HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice. , 2011, ACS nano.

[78]  Guanjun Chen,et al.  Magnetic characterization of noninteracting, randomly oriented, nanometer-scale ferrimagnetic particles , 2010 .

[79]  Trevor Douglas,et al.  Host–guest encapsulation of materials by assembled virus protein cages , 1998, Nature.

[80]  美和 赤祖父.  Immunohistochemical-detection of p53 in cervical epithelial lesions with or without infection of human papillomavirus types 16 and 18 , 1995 .

[81]  G. Pinkus,et al.  WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. , 2002, American journal of clinical pathology.

[82]  Randall G. Lee,et al.  Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.